Sutro Biopharma (STRO) Return on Equity (2018 - 2025)

Sutro Biopharma has disclosed Return on Equity across 8 years of filings, most recently posting 0.02% for Q4 2025.

• Return on Equity for Q4 2025 came in at 0.02%, up 2.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.02% (up 2.0% YoY), and the FY2025 annual result was 0.04%, up 4.0% from the prior year.
• Return on Equity came in at 0.02% for Q4 2025 at Sutro Biopharma, up from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.02% in Q4 2025 to a low of 0.01% in Q3 2023.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.01%.
• Across the five-year window, Return on Equity fell 1 bps in 2023 and grew 2 bps in 2025, its largest moves.
• Sutro Biopharma's Return on Equity stood at 0.0% in 2021, then sank by 51 bps to 0.01% in 2022, then slumped by 53 bps to 0.01% in 2023, then surged by 96 bps to 0.0% in 2024, then soared by 5432 bps to 0.02% in 2025.
• The last three Return on Equity figures came in at 0.02% (Q4 2025), 0.0% (Q3 2025), and 0.01% (Q2 2025), per Business Quant data.